Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
02. März 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Internally developed fully human anti-CD47 antibody (STI-6643) cleared for basket trial;No complicated titration or priming dose of the antibody is required to reduce toxicity;This study will be...